

# Ethnobotanical survey and some biological activities of *Ageratum conyzoides* collected in Southern-Benin

## ABSTRACT

**Aims:** *Ageratum conyzoides* L. is a small annual herbaceous highly odorous plant use in traditional medicine. The aim of this study is to evaluate *in vitro* antioxidant potential, toxicity and antimicrobial activity of aerial part extracts of *A. conyzoides* on strains potentially involved in vaginal infections.

**Methodology:** An ethnobotanical survey has been carried out on *A. conyzoides* among ethnobotanists and traditional therapists in fifteen markets in the communes of Abomey-Calavi, Cotonou, Zogbodomey, Bohicon and Abomey. The phytochemical screening was a qualitative analysis based on staining and precipitation reactions. Antimicrobial activity of *A. conyzoides* aqueous and ethanolic extracts was evaluated on reference and clinical strains of *Staphylococcus aureus*, *Candida albicans* and *Escherichia coli* using micro dilutions method in wells from . The toxicity of *A. conyzoides* extracts was determine using *Artemia salina* larvae, whereas the antiradical activity was evaluated using the Ferric Reducing Antioxidant Power (FRAP) method.

**Results:** The survey showed that the population of Southern-Benin uses *A. conyzoides* according to different modes of preparation. Also, the administration in the treatment of a variety of pathologies affecting the female reproductive system. The phytochemical screening revealed the presence of flavonoids, tannins, anthocyanins, triterpenes and C-heterosides. The yield of 6.18% for the aqueous extract and 4.32% for the ethanolic extract as recorded. The highest inhibition diameter ( $24.05 \pm 0.5$  mm) was obtained using aqueous extract against the clinical *S. aureus* strain. In contrast, the lowest inhibition diameter ( $10 \pm 0$  mm) was obtained against the *S. aureus* ATCC29213 with the same extract. The Minimum Inhibitory Concentration varied from 2.5 to 5 mg/ml. Both extracts show a bactericidal and fungicidal effect on the different strains studied but the sensitivity of the strains to the aqueous extract is better compared to the ethanolic extract. In addition, the aqueous extracts showed higher antioxidant power compared to the ethanolic extract. No toxicity is revealed for both extracts.

**Conclusion:** The results obtained show that the aqueous and ethanolic extracts of the aerial part of *A. conyzoides* have antioxidant and antimicrobial properties on strains involved in vaginal infections and do not present a toxicity.

**Keywords:** *Ageratum conyzoides*, antioxidant potential, antimicrobial activity, toxicity, *Staphylococcus aureus*, *Candida albicans*, *Escherichia coli*.

## 1. INTRODUCTION

Infectious diseases result from the interaction between an infectious agent, its host and environmental factors [1]. Those diseases cause numerous deaths per year worldwide in general and in developing countries in particular [2]. Among these diseases are genital infections, which are not only highly endemic in the African region [3], but more importantly, have serious consequences such as infertility, ectopic pregnancy, miscarriage, and increased risk of human immunodeficiency virus transmission. Depending on the location (vulva, vagina, and cervix) of the germ involved in the infection, we can have low and high infections [4]. Thus, Infectious diseases represent a global health problem in women of reproductive age and present in various forms (bacterial vaginosis, aerobic vaginosis,

23 vulvovaginal candidiasis, and trichomoniasis). Almost all major women are affected by a  
24 vaginal infection, sometimes recurrently, characterized by painful or embarrassing physical  
25 symptoms that can affect their life quality and self-esteem [5-6]. Vaginal infections are  
26 extremely prevalent [7], and are among the most common reasons for gynecological  
27 consultations in Benin [8]. To address genital infections, modern antimicrobials are  
28 commonly used. Incompetent diagnosis, inappropriate treatment, resistance to antimicrobial  
29 molecules, inaccessibility to modern care, high cost of drugs, and the manifestation of  
30 severe and in some cases toxic side effects are the main causes of unsatisfactory results of  
31 conventional treatment of these infections [9-10]. To face this problem, there is an urgent  
32 need for research to discover other active compound that can effectively treat genital  
33 infections. Thus, medicinal plants commonly used in traditional medicine could constitute an  
34 alternative source of new molecules with antimicrobial activity that are economically  
35 accessible [11-12] to populations with relatively very low-income levels. Considering that  
36 traditional practitioners hold an impressive number of plant-based recipes that can be used  
37 as a basis for screening, it makes sense to continue or even intensify research in this  
38 direction [13].

39 Indeed, plants are potential natural remedies that can be used in curative and preventive  
40 treatment [14], despite the advances in modern medicine. Thus, according to WHO  
41 estimates, 80% of the world's population use traditional medicine in the treatment of various  
42 ailments [15]. In Benin in particular, medicinal plants are used in the composition of  
43 pharmacopoeia products. Various medicinal plants are used for their biological properties in  
44 the treatment of many infectious pathologies [16]. Among these medicinal plants we can  
45 mention *Ageratum conyzoides*, used in many purposes such as treatment of several  
46 infections (genital, urinary, skin, oral, viral and eye) [17]. It is also known for its anti-  
47 inflammatory, antispasmodic, hypoglycemic, analgesic, anti-diarrheal, diuretic, antitussive,  
48 antirheumatic properties [18].

49 Several studies reported the use and potential antimicrobial activity of medicinal plants [17,  
50 19-21] including *A. conyzoides* [22]. However, it should be noted a lack of studies related to  
51 the antimicrobial activity of *A. conyzoides* in the specific treatment of vaginal infections.  
52 Thus, despite its medicinal use, the toxicity profile of the *A. conyzoides* plant remains to be  
53 explored and requires further studies. In order to strengthen the scientific knowledge on the  
54 medicinal usefulness of *A. conyzoides* and to contribute to its valorization this study is  
55 conducted. It aimed at evaluating the antioxidant potential, toxicity and antimicrobial activity  
56 of aerial part extracts of *A. conyzoides* plant on the growth of *C. albicans*, *E. coli* and *S.*  
57 *aureus* strains.

58

## 59 **2. MATERIAL AND METHODS**

### 60 **2.1. Ethnobotanical survey on the medicinal use of *A. conyzoides***

61 To investigate on the use of *A. conyzoides*, an ethnobotanical survey was conducted among  
62 herbalists, traditional practitioners, phytotherapists and all persons with endogenous  
63 knowledge in 5 municipalities of Southern-Benin (Bohicon, Abomey, Zogbodomey, Abomey-  
64 Calavi and Cotonou). The survey was conducted in the markets of Abomey-Calavi  
65 (Godomey, Agontikon, Ouédonou, Ouèdo, Togba, Calavi-Tokpa and Djadjo), Cotonou  
66 (Vèdoko, Gbégamey, Dantokpa and Sèdégbé); Zogbodomey (Massi and Zogbodomey),  
67 Bohicon and Abomey. During the survey, questions were asked through an individual  
68 interview using a survey form. These questions relate to information on the age, gender,  
69 level of education, professional experience and ethnicity of the respondents on the one  
70 hand; and on the vernacular name, selling price, different parts used, different pathologies  
71 treated, modes of preparation, modes of administration, contraindications and dosage of the  
72 plant on the other hand [23]. A total of 153 people were surveyed for this study in the 5  
73 municipalities between march and April 2022.

## 74 **2.2. Plant material samples collection**

75 After harvesting the plant was certified on April 11, 2022 at the National Herbarium of Benin  
76 (University of Abomey-Calavi) under the number YH696/HNB. Once identified, aerial part  
77 was washed and then dried at laboratory temperature ( $25 \pm 2^\circ\text{C}$ ) for two weeks. The dried  
78 sample was ground using a Retsch mechanical grinder type SM 2000/1430/Upm/Smf. The  
79 powder thus obtained were weighed and stored (protected from light) until their use for  
80 phytochemical screening and different extractions.

## 81 **2.3. Extractions of the plant powder**

82 Two types of extracts (aqueous and ethanolic) were performed. The choice of these types of  
83 extracts is based on the way the plant is traditionally used.

### 84 **2.3.1. Aqueous extract**

85 Maceration was used to get aqueous extract. Thus, 50 g of previously obtained powder was  
86 dissolved in 500 mL of distilled water and left under continuous stirring for 72 hours. The  
87 homogenate obtained was filtered twice successively on absorbent cotton and once on  
88 Whatman 1 paper. The filtrate was dried at  $50^\circ\text{C}$  and the powder obtained constituted the  
89 total aqueous extract.

### 90 **2.3.2. Ethanolic extract**

91 For the ethanolic extract, 50 g of powder was macerated under continuous stirring for 72  
92 hours in 500 ml of  $70^\circ$  ethanol. The mixture was then filtered to remove debris; this filtrate  
93 was optimized through additional filtration using a Whatman 1 paper. In order to remove  
94 ethanol, the solution was concentrated in a rotary evaporator at  $50^\circ\text{C}$  and stored at  $2-4^\circ\text{C}$   
95 to be used for further bioassays.

### 96 **2.3.3. Yield**

97 The extraction yield is the ratio of the mass of dry extract and the mass of plant material  
98 processed (Harborne, 1998). It was determined according to the formula:  $R (\%) = (Me/Mv) \times$   
99  $100$  with  $R (\%)$ : yield in %,  $Me$ : mass of dry extract,  $Mv$ : Mass of plant material used.

## 100 **2.4. Phytochemical screening**

101 The presence of metabolites was investigated directly on the plant powder. It is a qualitative  
102 analysis based on differential staining and precipitation reactions of the main groups of  
103 chemical compounds contained in the plant as described by Houghton and Raman [24] and  
104 used by Chabi-Sika et al. [16].

## 105 **2.5. Evaluation of the antimicrobial activity**

106 The antimicrobial activity was performed in three steps: susceptibility test, determination of  
107 the Minimum Inhibitory Concentration (MIC) and determination of the Minimum Bactericidal  
108 Concentration (MBC) / Fungal Concentration (FMC). Six microorganisms including three  
109 reference strains (*Staphylococcus aureus* ATCC29213, *Candida albicans* MHMR,  
110 *Escherichia coli* ATCC 25922) and three (03) strains isolated from vaginal swabs by Sina et  
111 al. [25] were used in this work for the antimicrobial activity.

### 112 **2.5.1. Sensitivity test**

113 The susceptibility of the microorganisms to the two extracts was performed using the Mueller  
114 Hinton (MH) solid media diffusion method, as previously described [16]. The sterile discs  
115 ( $\varnothing=6\text{mm}$ ) containing 30  $\mu\text{l}$  of each extract were deposited, under aseptic conditions, on  
116 previously inoculated microbial culture dishes. For each extract, the experiment is duplicated  
117 and a negative control is performed with distilled water. The plates are then left for 30 min at

118 room temperature before being incubated at 37°C in for 24 h and then 48 h. The inhibition  
119 diameters are measured after incubation times.

### 120 **2.5.2. Determination of the Minimum Inhibitory Concentration (MIC)**

121 The lowest concentration for which no growth is visible (MIC) was determined following the  
122 microdilution method using iodinitrotetrazolium (INT) as an indicator of bacterial viability  
123 [26]. Briefly, a range of nine concentrations (10 to 0.039 mg/ml) of the extracts was tested on  
124 the microbial strains. Indeed, 150 µl of distilled water was distributed in all wells (wells 1 to 9)  
125 of the plate and 150 µl of each extract (20 mg/ml) was added into the first wells. Successive  
126 dilutions of ½ ratio were then made from well 1 to well 9 and 150 µl of the last well was  
127 discarded. To end, 150 µl of bacterial inoculum (10<sup>6</sup> CFU/ml) was added to all wells. The  
128 microplate was covered with the parafilm paper and incubated at 37°C for 18 h. After  
129 incubation, 10 µl of para-INT violet solution (INT, 0.2 mg/ml) was added to all wells. Plates  
130 were re-incubated at 37°C for 30 min and the MIC is represented by the first well in which  
131 there is no appearance of red/pink staining.

### 132 **2.5.3. Determination of the Minimum Bactericidal/Fungal Concentration (MBC or** 133 **MFC)**

134 The lowest concentration at which 99.99% of germs are inhibited (MBC or MBC) was  
135 determined on the basis of the results of the determined MIC. Thus, after identifying the MIC,  
136 the content of wells with concentrations ≥ MIC were sought on petri dishes containing MH  
137 agar medium. The plates were examined after 24 h of incubation at 37°C. The antibacterial  
138 effect [27] will be considered as bactericidal or fungicidal (MBC or MFC/CMI ≤ 4) or  
139 bacteriostatic fungistatic (MBC or MFC/MIC ≥ 4).

### 140 **2.6. Larval toxicity evaluation**

141 The test is performed according to the method described by Kawsar et al. [28] and recently  
142 used by Chabi-Sika et al. [16]. Thus, larvae used are obtained by hatching 10 mg of *Artemia*  
143 *salina* eggs placed under continuous agitation in 1 L of seawater for 72 hours. A stock  
144 solution of 20 mg/ml per extract was prepared by adding DMSO. From extracts, a ½ ratio  
145 serial dilutions were made. To 1ml of each dilution, was added 1ml of seawater containing  
146 16 larvae. After 24h of incubation, the count of dead, moribund and live larvae was  
147 performed for the determination of LC<sub>50</sub>. If deaths were recorded among the control, the data  
148 were corrected by Abbott's formula: %death = [(test-control)/control] x 100.

### 149 **2.7. Antioxidant activity evaluation**

150 The reducing power of the extracts was determined by the Ferric Reducing Antioxidant  
151 Power (FRAP) method according to the protocol described by Dieng et al. [29]. Briefly, using  
152 a batch of 8 tubes (numbered from 1-8), 0.5ml of 25% DMSO were distributed in tubes 2 to 7  
153 and then 0.5ml of the extract (5 mg/ml) were introduced in tubes 1 and 2. A series of  
154 successive ½ dilution from tube 2 into all other tubes was then performed. In addition, 0.5 ml  
155 of sample at different concentrations was mixed with 1 ml of phosphate buffer (0.2M;  
156 pH=6.6) and 1 ml of 1% potassium hexacyanoferrate [K<sub>3</sub>Fe(CN)<sub>6</sub>]. After incubating the  
157 mixture at 50°C for 30 minutes, 1 ml of 10% trichloroacetic acid was added to stop the  
158 reaction, then the tubes were centrifuged at 3000 rpm for 10 minutes. Then, 1 ml of the  
159 supernatant from each tube was mixed with 0.2 ml of 0.1% FeCl<sub>3</sub> solution and allowed to  
160 stand in the dark for 30 min before measuring the optical densities (OD) at 700 nm. The  
161 antioxidant activity related to the reducing power of the extracts is expressed as Reducing  
162 Power (RP) using the following formula:  $RP = [OD (extract) - DO (blanc) / OD (extract)] \times 100$

### 163 **2.8. Data Analysis**

164 Collected data were encoded using Excel 2013 Spreadsheet. Data analyses were done  
165 using GraphPad Prism 8 software. For each extract, the lethal concentration that causes

166 50% larval death (LC<sub>50</sub>) was calculate with a 95% confidence interval by linear regression  
 167 analysis and also using the Probit analysis method following. A regression line equation,  
 168 obtained from the larval mortality curve, is used to calculate the concentration (LC<sub>50</sub>)  
 169 corresponding to the death of half the larvae. The degree of leaf toxicity was evaluated  
 170 based on the correspondence table established by Mousseux [30].  
 171

### 172 3. RESULTS AND DISCUSSION

173

#### 174 3.1. Results

175

##### 176 3.1.1 Ethnobotanical survey on the medicinal use of *A. conyzoides*

177

178 During this survey, it was revealed that *A. conyzoides* is well known by the population who  
 179 give it different names according the ethnics of southern-Benin (Table 1).

180 Table 1. Different names of *A. conyzoides* in the ethnics of southern-Benin

181

Ethnics	Names in the different ethnics
Goun	Awovitakin, Kouvito-takin and Soungnonu
Fon	Awovitakinman, Gnor-sounouman and Kouvito-takin
Xwla	Zounxosou, Azétorxontin and Togbé
Mahi	Assoukousi-xwawé

182

##### 183 3.1.2. Socio-demographic parameters of respondents

184

185 Table 2 presents the socio-demographic results of respondents. The table shows that the  
 186 extremes age are 20 years old and 80 years old with an average age of 44.22 ± 7.11 years  
 187 old. The majority of respondents had a primary (45.10%) or secondary (31.37%) education;  
 188 some of them had no schooling (22.22%) or rarely had a university education (1.31%). In  
 189 addition, 93.46% of the respondents are of Fon ethnicity followed by Goun (3.92%), Xwla  
 190 (1.96%) and Mahi (0.65%) ethnicity. The professional experience of the respondents varies  
 191 between 5 and 35 years, with 54.54% having professional experience ranging from 15 to 30  
 192 years, followed by those with experience ranging from 5 to 11 years (33.33%) and finally  
 193 12.12% with professional experience exceeding 30 years.

194 Table 2. Socio-demographic parameters of respondents


Sociodemographic Parameters	Workforce (N)	Proportions (%)
<b>Sex</b>		
Male	32	20.92
Female	121	79.08
<b>Age (Year)</b>		
[20;40[	45	29.41
[40;60[	99	64.71
[60;80[	9	5.88
<b>Professional experience (Year)</b>		
[5; 10[	19	12.42
[10; 15[	42	27.45
[15; 20[	46	30.07
[20; 25[	30	19.61
[25; 30[	8	5.23
[30; 35[	8	5.23
<b>Education level</b>		
Primary	69	45.10
Secondary	48	31.37

Superior	2	131
Unschooler	34	22.22
<b>Ethnic group</b>		
Fon	143	93.46
Goun	6	3.92
Xwla	3	1.96
Mahi	1	0.65

195  
196  
197  
198  
199  
200  
201

**3.1.3. Uses of the different parts of *Ageratum conyzoides* in Southern-Benin**

Figure 1 below presents the results of the medicinal and pharmacological use of the various parts of *A. conyzoides* in southern-Benin. It should be noted that the population uses this plant in the treatment of various pathologies. They mainly use the leaves (87.58%) and the stem (53.59%), sometimes the whole plant (14.38%), few uses roots (1.96%) and very rarely the flower (0.65%) of *A. conyzoides* (Figure 1).




202  
203

Figure 1: Proportions of respondents according to the different parts of *A. conyzoides*.

204  
205  
206  
207  
208  
209


In addition, it appears that the studied population uses this species essentially in the treatment of vaginal infections (32.08%), stomach aches (18.30%), skin infections (14.38%), female sterility (5.88%), pathologies affecting the female genital tract [painful periods (10.46%), blocked trunk (5.88%), cysts (1.96%)], wounds (7.84%), intestinal worms (7.19%), pain (5.23%), urinary tract infections (3.92%), diarrheal diseases (2.61%) and malaria (1.96%) (figure 2).



210

211 Figure 2. Distribution of the different pathologies reported to treated by *A. conyzoides*

212 To treat the various pathologies, the population uses this species alone or in combination in  
 213 various forms, namely decoction (72.55%), trituration (16.99%), maceration (14.38%),  
 214 infusion (9.8%) or carbonization (0.65%) (figure 3).




215

216 Figure 3. Preparation method of *A. conyzoides* in the study area

217  
218  
219  
220


Moreover, depending on the pathology to be treated and the preparation method, *A. conyzoides* can be administered orally (62.75%), dermally (36.60%), vaginally (14%) or rarely by the laryngeal route (0.65%) as shown in Figure 4.



221

222 Figure 4. Proportion of the administration routes of *A. conyzoides* based preparations in  
223 southern Benin

224 The duration of treatment shown in Figure 5 is generally indefinite (use until satisfaction) but  
225 varies according to the pathology. It ranges from 3 to 5 days in the treatment of stomach  
226 aches and pain, from 7 to 15 days in the treatment of infections, from 1 to 3 months in the  
227 treatment of infertility. However, the therapeutic use of this plant is limited in pregnant  
228 women. Also, its use is accompanied by some restrictions, namely: the intake of alcohol  
229 during the treatment, the combination with other drugs or pharmaceutical products during the  
230 treatment, the consumption of sticky sauces and the excessive consumption of red oil during  
231 its use.



232

233 Figure 5. Compilation of the *A. conyzoides* based preparations treatment duration in  
234 southern Benin

235 **3.1.4 Phytochemical screening of *Ageratum conyzoides***

236

237

238

239

240

241

242

243

244

The analysis of this table 3 shows that *A. conyzoides* contains a several secondary metabolites such as flavonoids, catechic tannins, gall tannins, anthocyanins, triterpenes and C-heterosides. However, leuco-anthocyanins, alkaloids, reducing compounds, mucilages, saponosides, steroids, coumarins, quinone derivatives, free anthracenics, O-heterosides, O-heterosides with reduced genines are absent. The plant does not contain cardiotoxic and cyanogenic derivatives either.

Table 3. Results of phytochemical screening of the leafy stem of *A. conyzoides*.

GROUPS OF METABOLITES	PRESENCE
Catechic tannins	+
Gallic tannins	+
Flavonoids	+
Leuko-anthocyanins	-
Anthocyanin	+
Alkaloids	-
Reducing compounds	-
mucilage	-
Saponosides	-
Cyanogenic derivatives	-
Triterpenes	+
Steroids	-
Coumarins	-
Quinone derivatives	-
Free anthracenes	-
C-glycosides	+
O-heterosides	-
O-heterosides with reduced genins	-
Cardiotonic derivatives	-

245

246

247


248

249

250

**3.1.5 Yield of the extracts**

Figure 6 shows the yield of the two extracts: aqueous and ethanolic. The analysis of this figure shows that the extraction yield of the aqueous extract (6.18%) is higher than that of the ethanolic extract (4.32%).



251  
252 **Figure 6.** Yield of *A. conyzoides* extracts  
253

254 **3.1.6 Antimicrobial activity of *A. conyzoides* extracts**

255  
256 **3.1.6.1. Sensitivity test**


257  
258 The results of the inhibition tests reveal that strains are very sensitive to the different extracts  
259 tested (Table 4). However, *Candida albicans* was more sensitive to the ethanolic extract  
260 (with an inhibition diameter of 18±0.5 mm and 16±0 mm respectively for *C. albicans* MHMR  
261 and clinical *C. albicans*) than to the aqueous extract (inhibition diameter of 12±0 mm and  
262 12±0.5 mm respectively for *C. albicans* MHMR and clinical *C. albicans*).

263 *Staphylococcus aureus* strains were most sensitive to the aqueous extract. However, clinical  
264 *S. aureus* was more sensitive (24.05±0.5 mm) than the reference strain *S. aureus*  
265 ATCC29213 (10±0 mm) with the same extract. Similarly, the reference strain *Escherichia*  
266 *coli* ATCC 25922 was more sensitive than the clinical strain with the aqueous extract  
267 respectively with an inhibition diameter of 14.5±0.5 mm and 10±0.5 mm.

268 Table 4. Inhibitory activity of the aqueous and ethanolic extracts of the aerial part of *A.*  
269 *conyzoides* towards the reference and clinical strains tested.

Strains Tested	Inhibition diameter (mm)			
	Aqueous extract		Ethanolic extract	
	24 h	48 h	24 h	48 h
<b><i>S. aureus</i> ATCC29213</b>	10.5±0.5	10±0	15±0.5	10±1
<b><i>C. albicans</i> MHMR</b>	11±1	12±0	18±0.5	17.5± 0.5
<b><i>E. coli</i> ATCC 25922</b>	14.5±0.5	-	13±0.5	11.5±0.5
<b>Clinical isolated <i>S. aureus</i></b>	24.5±0.5	10±1	10±0	11±1
<b>Clinical isolated <i>C. albicans</i></b>	12±0.5	10.5±0.5	15±0.5	16±0
<b>Clinical isolated <i>E. coli</i></b>	10.5±0.5	10±0.5	-	-

271 The clinical strains tested showed variable sensitivity in the presence of *A. conyzoides*  
 272 extracts (Figure 7). Over a period of 24 h and 48 h, the strains show a higher sensitivity  
 273 (75%) to the aqueous extract of the plant as opposed to the ethanolic extract (62.5%).



274 Aqueous extract 24 h Ethanolic extract 24 h Aqueous extract 48 h Ethanolic extract 48 h  
 275 Figure 7: Sensitivity rate of clinical strains to extracts.

276  
 277 **3.1.6.2. Minimum Inhibitory Concentration and Minimum Bactericidal or Fungal**  
 278 **Concentration**

279  
 280 Table 5 presents the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal or  
 281 Fungal Concentration (MBC or MFC) of the *A. conyzoides* extracts on the strains studied. As  
 282 a result, the minimum inhibitory concentrations of the extracts vary between 2.5 and 5  
 283 mg/ml. The MICs of the ethanolic extract of the reference strains of *S. aureus* and *E. coli* are  
 284 2.5 mg/ml and 5 mg/ml respectively. In contrast to the reference strains, the lowest MICs  
 285 were observed with the aqueous extract with MICs of  $3.75 \pm 1.25$  mg/ml (clinical *S. aureus*);  
 286 2.5 mg/ml (clinical *C. albicans*) and 2.5 mg/ml (clinical *E. coli*).

287 The MBC or MFC of both extracts on the different strains is 10 mg/ml. Both extracts are  
 288 bactericidal and fungicidal respectively on the clinical strains of *S. aureus* and *C. albicans*  
 289 but show no effect on the clinical strain of *E. coli*. Moreover, we notice that on the reference  
 290 strain of *C. albicans*, both extracts present a quasi-stable activity with the same MFC/MIC  
 291 ratio (2 mg/ml). They are therefore fungicidal on the reference strain of *C. albicans*.

292 Table 5. Minimum Inhibitory Concentrations (MIC) and Minimum Bactericidal Concentrations  
 293 (MBC) of the two extracts of *A. conyzoides* on the strains studied.

Strains	MIC and MBC (mg/ml) of <i>Ageratum conyzoides</i> on tested strains							
	Aqueous Extract				Ethanolic extract			
	MIC	MBC MBC	MBC/MIC MFC/MIC	Effects	MIC	MBC MFC	MBC/MIC MFC/MIC	Effects
<i>S. aureus</i> ATCC29213	5	10	2	Bactericidal	2.5	10	4	Bactericidal
<i>C. albicans</i> MHMR	5	10	2	Fungicidal	5	10	2	Fungicidal
<i>E. coli</i> ATCC 25922	5	-	-	-	5	10	2	Bactericidal
<i>Clinical S. aureus</i>	$3.75 \pm 1.25$	$10 \pm 0$	2.67	Bactericidal	5	10	2	Bactericidal

<b>Clinical <i>C. albicans</i></b>	2.5	10	4	Fungicidal	5	10	2	Fungicidal
<b>Clinical <i>E. coli</i></b>	2.5	-	-	-	-	-	-	-

294

295

296

297

298

299

300


301

302

303

### 3.1.6 Antioxidant activity

The results of antioxidant activity of the aqueous and ethanolic extracts of *A. conyzoides* and Beta-Hydroxy Acid (BHA) are presented in figure 8. The Beta-Hydroxy Acid (BHA) is used as a control in this study. This figure reveals that the aqueous and ethanolic extracts of the *A. conyzoides* plant sample show antioxidant activity with respective inhibitory half-concentrations ( $IC_{50}$ ) of 0.16 mg/ml and 0.41 mg/ml while the  $IC_{50}$  of the control (BHA) is 0.23 mg/ml. It should also be noted that the aqueous extract of the plant has a stronger antioxidant power than the ethanolic extract.



304

305

306

307

308

309

310

311

312

313

314

315

316

317

318


319

320

Figure 8:  $IC_{50}$  of aqueous and ethanolic extracts of *A. conyzoides*

### 3.1.7 Larval toxicity

Figure 9 shows the results of the toxicity tests of the aqueous and ethanolic extracts of the aerial part of *A. conyzoides* on the larvae of *Artemia salina*. The results showed variability in the lethality rate on *A. salina* larvae. The lethal concentrations ( $LC_{50}$ ) were determined using the linear regression curve equations for each extract. The highest  $LC_{50}$  was obtained with the ethanolic extract (4.84 mg/ml) and the lowest with the aqueous extract (4.28 mg/ml). It is found that for all the obtained graphs the correlation coefficient  $R^2$  is lower than 0.8. By referring to the scale of toxicity established by Mousseux (1995), the extracts whose  $LC_{50}$  higher than 0.1 mg/ml, are regarded as not presenting any toxicity. Indeed, the extracts tested on *A. salina* were found to be non-toxic at the doses tested. However, mortality of *A. salina* increases as the concentration of extracts increases. The sensitivity of the larvae to the extracts thus follows a dose-response relationship.



321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

Figure 9: Toxicity curve of aqueous and ethanolic extracts of *A. conyzoides*

### 3.2. Discussion

Antibiotic and antifungal treatment of infections is not always effective and refers to the use of medicinal plants [7]. In this study, the ethnobotanical survey conducted on *A. conyzoides* in southern-Benin showed that traditional practitioners and herbalists are the professionals who hold endogenous knowledge. These professionals are mostly female (79.08%) and have a primary school education (45.10%) with at least five years of professional experience. This could be explained by the fact that in Benin, selling items at the market is usually reserved for women. Our results are in agreement with those of Yapi et al. [17] in Côte d'Ivoire who showed that 93% of herbalists are female. However, their results show that 65% of herbalists are uneducated. Similarly, *A. conyzoides* is well known in the traditional treatment of various pathologies, in this case in the treatment of vaginal infections. The leaves and the stem are the parts of the plant most used essentially by maceration in water and by oral or cutaneous way. Our results are similar to those obtained in Côte d'Ivoire [17] revealing a strong use of *A. conyzoides* for antimicrobial purposes especially in the treatment of conditions that can lead to female infertility. Also, they showed that the drink from the leaves is mostly (43.18%) used and the oral route is the most frequently used (60.93%). The high use of leaves would be explained by the fact that this part of the plant is the seat of photosynthesis and secondary metabolites responsible for biological properties [31]. Similarly, Ouattara [32] and N'Guessan [33] in Côte d'Ivoire, have shown that drinking is the most requested mode of administration in traditional medicine for the fact that diseases can be related to bacterial, fungal and/or parasitic infections.

Furthermore, phytochemical screening of *A. conyzoides* leafy stem powder revealed the presence of secondary metabolites such as gall and catechin tannins, flavonoids, anthocyanins, triterpenes and C-heterosides. These results are little similar to those obtained recently in Cameroon [34] and previously by other researchers [35-37]. These different authors have shown that phytochemical analyses on *A. conyzoides* provide evidence for the presence of a wide variety of phytochemicals, such as alkaloids, tannins, terpenoids, chromenes, coumarin, flavonoids, saponins, glycosides, phenols, and resins. This difference could be explained probably to the difference between the organs of the plant used. Other factors that could be responsible for these variations are differences in detection methods, nature of the solvent, concentration and polarity of the solvent, collection area, nature of the soil, and stage of plant development [22, 38]. However, the absence of

357 cyanogenic derivatives and cardiotoxic heterosides shown by our results is confirmed by  
358 these different authors. The presence of these large groups of chemical compounds, would  
359 be at the origin of the pharmacological properties of this plant and could justify its empirical  
360 use in various traditional medicines and especially in the treatment of vaginal infections in  
361 South-Benin.

362 The majority of the constituents of plants used in the treatment of female infertility possess  
363 antimicrobial activities [18]. Thus, the antimicrobial activity of the extracts showed that the  
364 extracts had a broad spectrum of antimicrobial activities, inhibiting *S. aureus* ATCC29213, *C.*  
365 *albicans* MHMR, *E. coli* ATCC 25922, clinical *S. aureus*, *C. albicans* and *E. coli*. These  
366 results are in agreement with the work of other authors [39-41]. The results of these authors  
367 reveal on the one hand that the aqueous and ethanolic extracts showed potential  
368 antibacterial activity on *Alcaligenes viscolactis*, *Klebsiella aerogenes*, *Bacillus cereus* and *S.*  
369 *pyogenes* as well as on methicillin-resistant *S. aureus* (MRSA). On the other hand, the  
370 literature review conducted by Chahal et al. [42], reveals that *A. conyzoides* effectively  
371 suppressed the growth of the genera *Aspergillus*, *Alternaria*, *Candida*, *Fusarium*,  
372 *Phytophthora* and *Pythium*.

373 The antimicrobial activity of *A. conyzoides* extracts would thus be linked to a synergistic  
374 effect between the different phytochemical groups present, namely tannins, flavonoids and  
375 triterpenes, all of which have antibacterial activity according to the literature. For example,  
376 polyphenolic compounds such as flavonoids exhibit various biological activities and are  
377 attributed to their ability to form complexes with the microbial extracellular wall [40]. Tannins  
378 exhibit antiparasitic, antiseptic, antibacterial, antioxidant, and anti-inflammatory activity [43].  
379 Triterpenoids have antimicrobial, antifungal, analgesic, viro-static and immunostimulatory  
380 properties [44].

381 The Minimum Inhibitory Concentrations and Minimum Bactericidal Concentrations obtained  
382 are variable depending on the types of strains and the type of extract. In this study, the MICs  
383 are between 2.5 mg/ml and 5 mg/ml for the reference strains tested and for the clinical  
384 strains. These values are largely lower than those obtained by Odeleye et al. [45] in Nigeria  
385 who had found MICs values between 120 mg/ml and 200 mg/ml with *A. conyzoides* extracts  
386 on the studied strains. The differences may be explained by the extraction method, solvents  
387 used and the plant organ used. Therefore, depending on the extraction method, the solvent  
388 used and even the plant organ, the antimicrobial active ingredients will not have the same  
389 concentrations in the extracts. These low values obtained in our studies encourage the idea  
390 of the effectiveness of the antimicrobial activity of the extracts of *A. conyzoides* in the  
391 treatment of infectious pathologies due to the tested strains.

392 In this study, the BMCs are 10 mg/ml for the reference strains tested and for the clinical  
393 strains. Our results are contrary to those obtained by other authors with the ethanolic extract  
394 of *A. conyzoides* [39]. This difference could be justified by the microbial strains used. The  
395 ratio of MIC and BMC parameters the aqueous and ethanolic extracts all have a bactericidal  
396 and fungicidal effect on the different strains tested with the exception of the ethanolic extract  
397 towards clinical *Escherichia coli*. Also, in this study, the tested strains show a low sensitivity  
398 to the ethanolic extract (62.5%) contrary to the aqueous extract (75%). This could be  
399 explained by the fact that water better concentrated the secondary metabolites present in *A.*  
400 *conyzoides* compared to ethanol. This is justified by the higher yield (6.18%) given by the  
401 aqueous extract compared to the ethanolic extract (4.32%) in our study. These results are  
402 similar to those obtained by Wuyep et al. [40] in a similar study in Nigeria who showed that  
403 *A. conyzoides* gave a better yield (10.796%) with the aqueous solvent than the ethanolic  
404 solvent (6.409%) as well as a higher antifungal activity compared to the ethanolic extract.  
405 According to Ouattara et al. [46], water is used as the main solvent especially in the  
406 treatment of mycoses. This would justify on the one hand the use of this plant mainly in the  
407 form of maceration or decoction in water and on the other hand, the restriction of alcohol  
408 consumption during its use for more effectiveness.

409 In our study, the results of the antioxidant activity of the *A. conyzoides* extracts show that  
410 with an IC50 of 0.16 mg/ml, the aqueous extract of the plant presents a good antioxidant  
411 activity contrary to the ethanolic extract which presents an IC50 of 0.41 mg/ml. Our results  
412 are similar to those obtained by Acheampong et al. [47] in Ghana; It showed that methanolic  
413 extract of *A. conyzoides* has high antioxidant power between 7.82-1000 µg/ml against gallic  
414 acid. Acheampong et al. [47] showed that aqueous extracts of *A. conyzoides* possess  
415 remarkable antioxidant effects. The results obtained provide evidence that *A. conyzoides*  
416 extracts through the studied organs (leafy stem) exhibit antioxidant activity [48] and would  
417 therefore be useful as a free radical scavenger and thus would help in the treatment of many  
418 diseases caused by reactive oxygen species. These diseases include aging, inflammation,  
419 cancer, diabetes and in this case microbial infections. The antioxidant activity is due to the  
420 presence of major chemical groups including tannins and flavonoids. This result  
421 corroborates well with the phytochemical screening results presented above.

422 Toxicity evaluation of *A. conyzoides* extracts on shrimp larvae shows that the two leafy stem  
423 extracts do not show toxicity. The non-toxic character of these extracts, revealed by the  
424 toxicity test, comes to justify the results of the phytochemical screening which showed the  
425 absence of cardiotoxic heterosides, cyanogenic derivatives and quinonic derivatives which  
426 are generally toxic compounds [49]. Moreover, these results are contrary to those of Djeneb  
427 et al. [50] who showed in their study that when mice were treated orally with the 70%  
428 ethanolic extract of *A. conyzoides* that no death of the mice was observed in the experiment  
429 but that the presence of slightly toxic effects on proliferating human HFF cells and an  
430 increase in the activity of cells that no longer divide were still noted.

#### 432 **4. CONCLUSION**

433  
434 An ethnobotanical survey was conducted on the use of *A. conyzoides* in the traditional  
435 treatment of infections. This survey, carried out among herbalists and traditional therapists in  
436 Abomey-Calavi, Cotonou, Zogbodomey, Bohicon and Abomey, revealed its strong  
437 therapeutic use by the populations in the treatment of genital affections, mainly vaginal  
438 infections. The present work allowed to highlight the antimicrobial and antioxidant properties  
439 and the toxic power of the different aqueous and ethanolic aerial parts extracts of *A.*  
440 *conyzoides*. The evaluation of the toxicity of the said extracts on shrimp larvae shows that  
441 they do not present larval cytotoxicity. The leafy stem of *A. conyzoides* presents a chemical  
442 profile that justifies its antimicrobial and antioxidant power and the safety of its use in human  
443 health. These results allow us to suggest the use of the aqueous extract of the leafy stem of  
444 *A. conyzoides* in the traditional treatment of vaginal infections. However, further studies need  
445 to be conducted to determine the appropriate dosage for safer human use.

#### 447 **COMPETING INTERESTS**

448  
449 Authors have declared that no competing interests exist.

#### 451 **AUTHORS' CONTRIBUTIONS**

452  
453 'KC-S, HS, GD, BB and GAD' designed the study, performed the statistical analysis, wrote  
454 the protocol, and wrote the first draft of the manuscript. 'KC-S, IM-S, HAS, AS, NM, DD-N  
455 and LB-M' managed the analyses of the study. 'HS, GAD, HL, GD and BB' managed the  
456 literature searches. All authors read and approved the final manuscript.

#### 458 **REFERENCES**

459

- 460 1. Cuzin L, Delpierre C. Epidemiologie des maladies infectieuses. EMC-Mal infect.  
461 2005. 2(1) :157-62.
- 462 2. Holmes KK, Bertozzi S, Bloom BR, et al. Major Infectious Diseases: Key Messages  
463 from Disease Control Priorities, Third Edition. *In*: Holmes KK, Bertozzi S, Bloom BR,  
464 et al., editors. Major Infectious Diseases. 3rd edition. Washington (DC): The  
465 International Bank for Reconstruction and Development / The World Bank; 2017 Nov  
466 3. Chapter 1. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK525197/> doi:  
467 10.1596/978-1-4648-0524-0\_ch1
- 468 3. WHO. 2002. Strategy for Traditional Medicine for 2002-2005, OMS/WHO ed.  
469 Geneva, 65p. (French)
- 470 4. Pellati D, Mylonakis I, Bertoloni G, Fiore C, Andrisani A, Ambrosini G, Armanini D.  
471 Genital tract infections and infertility. *Eur J Obstet Gynecol Reprod Biol.* 2008.  
472 140(1): 3-11. DOI: <http://doi:10.1016/j.ejogrb.2008.03.009>.
- 473 5. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C.  
474 The burden of bacterial vaginosis: Women's experience of the physical, emotional,  
475 sexual and social impact of living with recurrent bacterial vaginosis. *PLoS One* 2013;  
476 8(9): e74378. <http://dx.doi.org/10.1371/journal.pone.0074378>.
- 477 6. Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: A  
478 Current Understanding and Burning Questions. *J Fungi.* 2020; 6(1), 27.  
479 <https://doi.org/10.3390/jof6010027>
- 480 7. Palmeira-de-Oliveira R., Palmeira-de-Oliveira A., Martinez-de-Oliveira J., 2015. New  
481 strategies for local treatment of vaginal infections. *Adv. Drug Deliv. Rev.* 92, 105-  
482 122.
- 483 8. Tonato Bagnan JA, Denakpo JL, Aguida B, Hounkpatin L, Lokossou A, De Souza J,  
484 Perrin RX. Epidemiology of the gynecological and mammary cancer to the HOMEL  
485 and in the CUGO Cotonou, Benin. *Bull Cancer*, 2013; 100(2), 141-146.
- 486 9. WHO (World Health Organization), Antimicrobial Resistance. Regional Office for the  
487 Western Pacific, Seventieth Session Manila, Philippines. 2019; 8p. (French)
- 488 10. Superti F, De Seta F. Warding off recurrent yeast and bacterial vaginal infections:  
489 *Lactoferrin* and *Lactobacilli*. *Microorganisms.* 2020; 8(1),  
490 130.doi:10.3390/microorganisms8010130
- 491 11. Sanogo R, Diallo D, Diarra S, Ekoumou C, Bougoudogo F. Activité antibactérienne  
492 et antalgique de deux recettes traditionnelles utilisées dans le traitement des  
493 infections urinaires et la cystite au Mali. *Mali Méd.* 2006 ; Tome 21(1) :18.
- 494 12. Dembélé LD, Dramé BSI, Haïdara M, Koné C, Sanogo R. Paramètres  
495 physicochimiques et activité antibactérienne de trois plantes médicinales, utilisées  
496 dans la prise en charge des infections urinaires au Mali. *J Soc Ouest-Afr Chim.*  
497 2022 ; 51 : 10-16
- 498 13. Biswas B, Rogers K, Claughin F, Daniels D, Yadav A. Antimicrobial Activities of Leaf  
499 Extracts of Guava (*Psidium guajava* L.) on Two Gram-Negative and Gram-Positive  
500 Bacteria. *Int J Microbiol.* 2013, ID 746165, 7 p <https://doi.org/10.1155/2013/746165>
- 501 14. Oullai L, Chamek C. Contribution to the ethnopharmacognosic study of medicinal  
502 plants used for the treatment of digestive tract disorders in Kabylie. Dissertation  
503 Doctor of Pharmacy, Mouloud Mammeri University, Faculty of Medicine, 2018,  
504 199pp. (French)
- 505 15. WHO/MS-Benin, WHO Country Cooperation Strategy 2009–2013 Benin. WHO  
506 Regional Office for Africa, 2009. ISBN: 978 929 031 1249 (NLM Classification: WA  
507 540 HB35)
- 508 16. Chabi-Sika K, Sina H, Boya B, Bade F, Hounnou T, Badoussi ME, Adjatin A, Baba-  
509 Moussa L. *Richardia brasiliensis* collected in Southern-Benin: Phytochemical,  
510 Antimicrobial Activity and Toxicity. *Asian J Biol.* 2021; 13(4):22-23.
- 511 17. Yapi AB, Kassi NJ, Fofie NBY, Zirih GN. Etude ethnobotanique des Asteraceae  
512 médicinales vendues sur les marchés du district autonome d'Abidjan (Côte d'Ivoire).

- 513 Int J Biol Chem Sci. 2015; 9(6): 2633-47. DOI :  
514 <http://dx.doi.org/10.4314/ijbcs.v9i6.10>
- 515 18. Telefo PB, Lemfack MC, Bayala B, Lienou LL, Goka CS, Yemele MD, Mououkeu C,  
516 Tagne SR, Moundipa FP. Enquête ethnopharmacologique des plantes utilisées  
517 dans le traitement de l'infertilité féminine dans les localités de Fossong-Wentcheng  
518 et Foto, Cameroun. *Phytothérapie*. 2012 ; 10(1) : 25-34.
- 519 19. Akegninou A, van der Burg WJ, van der Maesen LJO, Adjakidjè V, Essou JP, Sinsin  
520 B, Yédomonhan H. Flore Analytique du Bénin. Université d'Abomey-Calavi,  
521 Cotonou, République du Bénin. Cotonou & Wageningen. Backhuys Publishers,  
522 2006. 1034p.
- 523 20. Fanou BA, Klotoe JR, Fah L, Dougnon V, Koudokpon CH, Toko G, Loko F.  
524 Ethnobotanical survey on plants used in the treatment of candidiasis in traditional  
525 markets of southern Benin, *BMC Complementary Med Ther*. 2020, 20(1), 1-18.
- 526 21. Akabassi BS, Djossou JA, Tchobo PF, Tchatcha DA, Houénon GHA, Yovo M,  
527 Dédjiho CC, Bogninou-Agbidinokoun RSG, Soumanou MM. Criblage  
528 phytochimique et évaluation des activités antiradicalaire et antimicrobienne des  
529 organes du *Detarium microcarpum* Guill. & Perr de la zone soudanienne du Bénin. *J*  
530 *Soc Ouest-Afr Chim*. 2021 ; 050 ; 68- 75
- 531 22. Adjou ES, Aoumanou MM. Efficacité des extraits de plantes dans la lutte contre les  
532 moisissures toxigènes isolées de l'arachide en post-récolte au Bénin. *J Appl*  
533 *Biosci*. 2013 ; 70, 5555-66.
- 534 23. Roko OG, Dougnon V, Hounkpatin A, Klotoé JR, Baba-Moussa L. Anti-inflammatory,  
535 Analgesic and Antipyretic Properties of Ethanolics Extrats of Three Plants of  
536 Beninese's Pharmacopoeia: *Euphorbia hirta*, *Citrus aurantifolia* and *Heterotis*  
537 *rotundifolia*. *Asian J Biol*. 2019, 8(4) :1-8.
- 538 24. Houghton P, Raman J, 1998. A Laboratory handbook for the fractionation of natural  
539 extracts. Chapman et Hall, London, 199 p
- 540 25. Sina H, N'tcha C, Dah-Nouvlessounon D, Gnama-Tchao G, Boya B, Socohou A,  
541 Sanni ARA, Baba-Moussa F, Adjanohoun A, Baba-Moussa L. Molecular  
542 characterization of high-risk infection vaginal bacteria isolated from pregnant women  
543 in CHU-MEL of Cotonou (Benin). *Afr J Microbiol Res*. (2021); 15(12), 592-604.
- 544 26. Amoussa AMO, Sanni A and Lagnika L. Antioxidant activity and the estimation of  
545 total phenolic, flavonoid and flavonol contents of the bark extracts of *Acacia*  
546 *ataxacantha*. *J Pharmacogn Phytochem*. 2015; 4(2) :172-178.
- 547 27. Kamanzi AK. Medicinal plants of Côte d'Ivoire: phytochemical investigations guided  
548 by biological tests. Doctoral thesis, University of Cocody, Abidjan, Ivory Coast. 2002;  
549 176p
- 550 28. Kawsar SMA, Huq E, Nahar N. Cytotoxicity assessment of the aerial parts of  
551 *Macrotyloma uniflorum* linn. *Intl J Pharmacol*. 2008; 4(4), 297-300.
- 552 29. Dieng SIM, Fall AD, Diatta-Badji K, Sarr A, Sene M, Sene M, Mbaye A, Diatta W,  
553 Bassene E. Evaluation de l'activité antioxydante des extraits hydro-ethanoliques des  
554 feuilles et écorces de *Piliostigma thonningii* Schumach. *Int J Biol Chem Sci*. 2017;  
555 11(2): 768-776
- 556 30. Mousseux M. Toxicity test on *Artemia salina* larvae and maintenance of a farm and  
557 blanes, second year internship report. DEUST Aquaculture ; University Center of  
558 New Caledonia, France, 1995 ; (French)
- 559 31. Mangambu M, Mushagalusa K, Kadima N. Contribution à l'étude phytochimique de  
560 quelques plantes médicinales antidiabétiques de la ville de Bukavu et ses environs  
561 (Sud-Kivu, R.D. Congo). *J Appl Biosci*. 2014 ; 75: 6211-20.  
562 <http://dx.doi.org/10.4314/jab.v75i1>
- 563 32. Ouattara D. Contribution to the inventory of significant medicinal plants used in the  
564 Divo region (southern forest of the Ivory Coast) and to the diagnosis of the Guinea  
565 pepper plant: *Xylopiya aethiopica* (Dunal) A Rich (*Annonaceae*). Doctoral thesis

- 566 University of Cocody, Abidjan (Ivory Coast), UFR Biosciences, 2006. 184 p.  
567 (French)
- 568 33. N'Guessan K. Medicinal plants and traditional medical practices among the Abbey  
569 and Krobou peoples of the Department of Agboville (Ivory Coast). State Doctorate  
570 Thesis, University of Cocody-Abidjan, U.F.R. Biosciences. 2008; 235 p. (French)
- 571 34. Ndacnou MK, Pantaleon A, Tchinda JS, Mangapche ELN, Keumedjio F, Boyoguemo  
572 DB. Phytochemical study and anti-oomycete activity of *Ageratum conyzoides*  
573 Linnaeus. Industrial Crop Products. 2020, 153, 112589.  
574 <https://doi.org/10.1016/j.indcrop.2020.112589>
- 575 35. Kasali AA, Winterhalter P, Adio AM, Knapp H, Bonnlander B. Chromenesin  
576 *Ageratum conyzoides* L. Flavour Fragr J. 2002; 17: 247-50.
- 577 36. Usman LA, Zubair MF, Olawore NO, Muhammad NO, M'Civer FA, Ismaeel RO.  
578 Chemical constituents of flower essential oil of *Ageratum conyzoides* growing in  
579 Nigeria. Elixir Org Chem. 2013; 54:12463-5.
- 580 37. Okereke SC, Chukwudoruo CS, Nwaokezie CO. Phytochemical screening using  
581 GC-FID and sub-chronic assessment of Hydroethanolic leaf extract of *Ageratum*  
582 *conyzoides* Linn. On albino rats. J Med Plants Stud. 2017; 5: 282-7.
- 583 38. Folashade KO, Omoregie EH, Ochogu AP. Standardization of herbal medicines-A  
584 Review. Int J Biodiver Conserv. 2012; 4(3): 101-112
- 585 39. Akinyemi KO, Oladapo O, Okwara CE, Ibe CC, Fasura KA. Screening of crude  
586 extracts of six medicinal plants used in South-West Nigerian unorthodox medicine  
587 for anti-methicillin resistant *Staphylococcus aureus* activity. BMC Complementary  
588 Altern Med. 2005; 5(1): 1-7
- 589 40. Wuyep PA, Musa HD, Ezemokwe GC, Nyam DD, SilaGyang MD. Phytochemicals  
590 from *Ageratum conyzoides* L. Extracts and their Antifungal Activity against Virulent  
591 *Aspergillus* spp. J Academia Industrial Res. 2017; 6(3): 32-39.
- 592 41. Omole OA, Oladipo JO, Orimolade BO, Ajetomobi OO, Olorumaiye KS, Dosumu  
593 OO. Anti-Oxidant and Anti-Microbial Activities of the Root and Leaf Extracts of  
594 *Ageratum conyzoides* L. Agriculture Conspectus Scientificus. 2019; 84(3):295-304.
- 595 42. Chahal R, Nanda A, Akkol EK, Sobarzo-Sánchez E, Arya A, Kaushik D, Dutt R,  
596 Bhardwaj R, Rahman MH, Mittal V. *Ageratum conyzoides* L. and Its Secondary  
597 Metabolites in the Management of Different Fungal Pathogens. Molecules. 2021; 26,  
598 2933. <https://doi.org/10.3390/>
- 599 43. Yessoufou A, Gbenou J, Grissa O, Hichami A, Simonin A-M, Tabka Z, Moudachirou  
600 M, Moutairou K, Khan NA. Anti-hyperglycemic effects of three medicinal plants in  
601 diabetic pregnancy: modulation of T cell proliferation. BMC Complementary Altern  
602 Med. 2013; 13(77) 13p.
- 603 44. Connolly JD, Hill RA. Triterpenoids. Natural Product Reports. 2007; 24: 465-486.
- 604 45. Odeleye OP, Oluyege JO, Aregbesola OA, Odeleye PO. Evaluation of preliminary  
605 phytochemical and antibacterial activity of *Ageratum conyzoides* (L.) on some  
606 clinical bacterial isolates. Int J Eng Sci. 201; 3: 1-5.
- 607 46. Ouattara KE, Doga D, Zirih GN. Evaluation In Vitro du Pouvoir Fongicide des  
608 Extraits De *Erigeron floribundus* (Kunth.) Sch. Bip. (Asteraceae) sur *Sclerotium*  
609 *rolfsii* et *Colletotrichum musae* Deux Champignons Phytopathogènes. Eur Sci J.  
610 2019; 15(9) : 370. <https://doi.org/10.19044/esj.2019.v15n9p370>
- 611 47. Acheampong F, Larbie C, Arthur FKN, Appiah-Opong R, Tuffour I. Antioxidant and  
612 anticancer study of *Ageratum conyzoides* aqueous extracts. J Global Biosci. 2015;  
613 4(1):1804-15.
- 614 48. Bédié AP, N'guessan BB, Yapo AF, N'guessan JD, Djaman JA. Activités  
615 antioxydantes de dix plantes médicinales de la pharmacopée ivoirienne. Sci Nat.  
616 2011 ; 8(1):1 -11

- 617 49. Hounbèmè AG, Gandonou C, Yehouenou B, Kpoviessi SDS, Sohounhloue D,  
618 Moudachirou M, Gbaguidi FA. Phytochemical analysis, toxicity and antibacterial  
619 activity of Benin medicinal plants extracts used in the treatment of sexually  
620 transmitted infections associated with HIV/AIDS. Int J Pharmaceutical Sci Res.  
621 2014 ; 1739-1745.
- 622 50. Djeneb C, Basile YA, Yvette BNF, Etienne OK, Noël ZG. Etude Comparative des  
623 Toxicités Cellulaires et Aigües de *Ageratum conyzoides* L. et de *Acanthospermum*  
624 *hispidum* DC. Eur Sci J. 2021; 17(40), 74.  
625 <https://doi.org/10.19044/esj.2021.v17n40p74>

626  
627